Evaluating Vaccine Efficacy and Immunogenicity in High-Risk Population

CERVAVAC®, a domestically developed quadrivalent human papillomavirus (HPV) vaccine by Serum Institute of India Pvt. Ltd., received marketing authorization from the Drugs Controller General of India (DCGI) in July 2022. This Phase 3b clinical trial (NCT06281119) aims to evaluate the safety and immunogenicity of CERVAVAC® in 450 women living with HIV, aged 15-25, who are considered a high-risk population with a cervical cancer incidence rate up to six times higher than the general population. Individuals with HIV infection have compromised immune systems, making them more susceptible to multiple HPV infections and the progression to cervical intraepithelial neoplasia (CIN). Therefore, demonstrating the vaccine's ability to elicit a robust immune response in this population is crucial for both commercial and clinical success.

This study is being conducted in Kenya, Mozambique, and South Africa, with approximately $4.25 million in funding from the Bill & Melinda Gates Foundation, highlighting its focus on providing accessible preventative medicine to underserved global populations.

Optimizing Dosage Schedule and Administration Route for Improved Convenience

The clinical trial compares a three-dose CERVAVAC® regimen, a two-dose CERVAVAC® regimen, and a three-dose regimen of Gardasil®, the quadrivalent vaccine from MSD, in a 1:1:1 randomization ratio. If the two-dose CERVAVAC® schedule demonstrates non-inferiority in terms of immune response compared to the three-dose regimen, it could significantly reduce barriers to public health access in low- and middle-income countries (LMICs) with limited vaccine budgets. Reducing the number of doses can greatly improve patient compliance and increase vaccination rates in regions with limited healthcare infrastructure. The global scientific community and market anticipate that the success of the two-dose protocol will significantly impact vaccine distribution speed and efficiency.

Market Penetration Strategy Through Head-to-Head Comparison with MSD's Gardasil®

A key aspect of this trial is the direct, head-to-head comparison of CERVAVAC® with Gardasil®, the dominant vaccine in the global market, to evaluate immune responses. CERVAVAC® is India's first domestically developed vaccine, manufactured using in-house technology, and is priced at approximately 200-400 rupees per dose, which is about one-tenth the price of Gardasil®. If CERVAVAC® demonstrates comparable efficacy in the high-risk population, it could emerge as a strong alternative with the potential to disrupt the global HPV vaccine market. This would provide Serum Institute of India with a significant advantage in capturing market share in LMICs, where MSD has traditionally held a dominant position.

Overcoming Regulatory Hurdles for Access to the Global Public Health Procurement Market

Serum Institute plans to use the data from this Phase 3b trial to pursue prequalification (PQ) from the World Health Organization (WHO). WHO PQ approval is a critical step for accessing global public procurement mechanisms, such as UNICEF and Gavi, to supply the vaccine to low-income countries worldwide. The global HPV vaccine market, currently valued at approximately $5.4 billion in 2024, is projected to grow to over $12.1 billion by 2030, with a significant portion of this market being public procurement. Therefore, securing safety and immunogenicity data from this multi-country African trial is a key regulatory milestone for expanding into the global market.